NO970374L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO970374L
NO970374L NO970374A NO970374A NO970374L NO 970374 L NO970374 L NO 970374L NO 970374 A NO970374 A NO 970374A NO 970374 A NO970374 A NO 970374A NO 970374 L NO970374 L NO 970374L
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO970374A
Other languages
English (en)
Norwegian (no)
Other versions
NO970374D0 (no
Inventor
Michael Joseph Browne
Kay Elizabeth Murphy
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Peter Ronald Young
Allan Richard Shatzman
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415379A external-priority patent/GB9415379D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO970374D0 publication Critical patent/NO970374D0/no
Publication of NO970374L publication Critical patent/NO970374L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO970374A 1994-07-29 1997-01-28 Nye forbindelser NO970374L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415379A GB9415379D0 (en) 1994-07-29 1994-07-29 Novel compounds
US46829795A 1995-06-06 1995-06-06
PCT/EP1995/003036 WO1996004388A1 (en) 1994-07-29 1995-07-28 Novel compounds

Publications (2)

Publication Number Publication Date
NO970374D0 NO970374D0 (no) 1997-01-28
NO970374L true NO970374L (no) 1997-02-19

Family

ID=26305369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970374A NO970374L (no) 1994-07-29 1997-01-28 Nye forbindelser

Country Status (13)

Country Link
EP (1) EP0770135A1 (zh)
JP (1) JPH10503371A (zh)
CN (1) CN1117155C (zh)
AU (1) AU3382595A (zh)
BR (1) BR9508469A (zh)
CA (1) CA2196200A1 (zh)
CZ (1) CZ25697A3 (zh)
HU (1) HUT76369A (zh)
MX (1) MX9700764A (zh)
NO (1) NO970374L (zh)
NZ (1) NZ292124A (zh)
PL (1) PL182665B1 (zh)
WO (1) WO1996004388A1 (zh)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6287801B1 (en) * 1996-07-22 2001-09-11 Smithkline Beecham Corporation Nucleic acids encoding the G-protein coupled receptor HNFDS78
EA004790B1 (ru) * 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
ATE470858T1 (de) * 2001-02-22 2010-06-15 Univ New York State Res Found Opiatrezeptoren
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7371383B2 (en) 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
ATE530577T1 (de) 2002-05-10 2011-11-15 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2004067026A1 (en) * 2003-01-18 2004-08-12 Children's Hospital Medical Center Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
BRPI0408315A (pt) 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
DE602004011770T2 (de) * 2003-06-12 2009-02-05 Eli Lilly And Co., Indianapolis Fusionsproteine
KR100758755B1 (ko) * 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン，エルエルシー 抗体のヒト化
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
SI1751184T1 (sl) * 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
CN101529253A (zh) 2006-06-21 2009-09-09 阿珀吉尼科斯有限公司 Il-4和/或il-10细胞因子在人癌症中的差异表达
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
CA2685213C (en) 2007-05-04 2017-02-21 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
SG10201503254TA (en) 2007-05-14 2015-06-29 Medimmune Llc Methods of reducing eosinophil levels
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
CN102083460A (zh) 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101030978B1 (ko) * 2008-07-10 2011-04-28 (주) 에이프로젠 동물세포용 재조합 발현벡터
JP5815403B2 (ja) 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
AU2009350151B2 (en) 2009-07-20 2015-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011018421A1 (en) 2009-08-10 2011-02-17 Morphosys Ag Novel screening strategies for the identification of binders
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
NZ603488A (en) 2010-07-09 2015-02-27 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CN103080134B (zh) 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
KR20140014064A (ko) 2010-09-03 2014-02-05 스템 센트알엑스 인코포레이티드 신규한 조절 인자 및 사용 방법
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013043071A1 (en) 2011-09-23 2013-03-28 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
TW201328707A (zh) 2011-12-05 2013-07-16 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
CA2865415C (en) 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
MX368067B (es) 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
KR20160037130A (ko) 2013-02-22 2016-04-05 스템센트알엑스 인코포레이티드 신규한 항체 접합체 및 이의 용도
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
SI2970473T1 (sl) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
CN103265637B (zh) * 2013-06-04 2015-10-21 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法
SG11201509982UA (zh) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
DK3041507T3 (da) 2013-08-26 2021-07-26 Biontech Res And Development Inc Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
PE20161413A1 (es) 2013-11-04 2017-01-10 Stemcentrx Inc Conjugados de anticuerpo anti-efna4-farmaco
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
CU24453B1 (es) 2014-08-07 2019-11-04 Novartis Ag Anticuerpos anti proteína similar a angiopoyetina 4
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
AU2015311911B2 (en) 2014-09-03 2019-01-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PT3333191T (pt) 2014-12-11 2020-12-15 Pf Medicament Anticorpos anti-c10orf54 e suas utilizações
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112017015880A2 (pt) 2015-03-03 2018-07-31 Kymab Ltd anticorpos, usos e métodos
US10047155B2 (en) 2015-06-05 2018-08-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
CN108473555B (zh) 2015-11-02 2022-10-25 生物蛋白有限公司 条件活性多肽
KR20210016479A (ko) 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
UY37030A (es) 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102602137B1 (ko) 2016-07-06 2023-11-13 브리스톨-마이어스 스큅 컴퍼니 Tim-4 길항제 및 pd-1 길항제의 조합물 및 사용 방법
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018116267A2 (en) 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
CA3048156A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
MX2019009498A (es) 2017-02-08 2019-10-02 Novartis Ag Anticuerpos mimeticos de fgf21 y usos de los mismos.
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
SG11202111281TA (en) 2019-05-21 2021-12-30 Novartis Ag Cd19 binding molecules and uses thereof
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
US20230227545A1 (en) 2022-01-07 2023-07-20 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung

Also Published As

Publication number Publication date
AU3382595A (en) 1996-03-04
EP0770135A1 (en) 1997-05-02
PL318380A1 (en) 1997-06-09
JPH10503371A (ja) 1998-03-31
PL182665B1 (pl) 2002-02-28
CA2196200A1 (en) 1996-02-15
CN1117155C (zh) 2003-08-06
MX9700764A (es) 1997-05-31
BR9508469A (pt) 1997-09-16
WO1996004388A1 (en) 1996-02-15
NZ292124A (en) 1998-10-28
HUT76369A (en) 1997-08-28
NO970374D0 (no) 1997-01-28
CZ25697A3 (en) 1997-09-17
CN1164872A (zh) 1997-11-12

Similar Documents

Publication Publication Date Title
NO970374L (no) Nye forbindelser
NO973231D0 (no) Nye forbindelser
NO960472D0 (no) Nye forbindelser
NO20000312L (no) Nye forbindelser
NO303016B1 (no) Nye forbindelser
NO20002787D0 (no) Nye forbindelser
FI955927A (fi) Substituoidut 1H-imidatsolit
NO970512D0 (no) Nye heteroaryl-oksazolidinoner
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
NO983356D0 (no) Nye 19-nor-pregnenderivater
DE69534718D1 (de) Substituierte 9-alkyladenine
DK0906288T3 (da) Nye forbindelser
FI942119A0 (fi) Anordning i en gasblandare
DK0770132T3 (da) Nye streptograminer
NO960268D0 (no) Nye dialkoksypyridinylbenzimidazolderivater
NO990072D0 (no) Nye forbindelser
BR9509559A (pt) Azolilulsolfonilfeniluracilas substituídas
NO940195L (no) Nye forbindelser
NO991097D0 (no) Nye fremgangsmÕter
FI1516U1 (fi) Foerpackning foer i stapel anordnade smaoark
NO983505D0 (no) Nye fenantrider
DE59510274D1 (de) Substituierte biphenyloxazoline
FI1570U1 (fi) Instaellbart vinkelstycke foer central dammsugare
BR7401569U (pt) Central eletro-eletrônica
FI1839U1 (fi) Larmapparat foer fast montering i en byggnad

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application